The development of mdprostate embodies the result of extensive research and dedicated teamwork. As an automated solution for assessing prostate MRI scans according to PI-RADS 2.1, it provides reliable diagnostic support and meets the strict quality and safety guidelines essential for use in clinical practice.
Our close collaboration with numerous radiologists from prestigious institutions has provided us with valuable insights that have led to the continuous optimization of mdprostate. Together, we have impressively demonstrated our leadership in developing AI software for radiology.
Andreas Lemke, our CEO, highlights this with the following statement: "Once again, we have proven that, as an innovative company with a full focus on software development, we can rapidly and efficiently create AI applications for radiology. Our solutions always aim to create maximum value in radiological routines, and mdprostate is no exception. Therefore, it was important for us to develop a fully automated end-to-end solution, which, to our knowledge, is not yet available in the market. Currently, the product's performance is already on par with global study results. However, we do not rest on this success. In the coming months, we will work intensively to further enhance its accuracy. Only in this way can automation unleash its full potential for efficiency."
We cordially invite you to visit our website, to learn more details about mdprostate. We are proud of our team and look forward with anticipation to the future. We will continue to channel all our energy into collaboratively developing innovative solutions for sustainable diagnostics with our users.